UY30840A1 - Derivados de isoquinolina e isoquinolinona sustituidos - Google Patents

Derivados de isoquinolina e isoquinolinona sustituidos

Info

Publication number
UY30840A1
UY30840A1 UY30840A UY30840A UY30840A1 UY 30840 A1 UY30840 A1 UY 30840A1 UY 30840 A UY30840 A UY 30840A UY 30840 A UY30840 A UY 30840A UY 30840 A1 UY30840 A1 UY 30840A1
Authority
UY
Uruguay
Prior art keywords
isoquinolinona
isoquinolin
substituted derivatives
kinase
prevention
Prior art date
Application number
UY30840A
Other languages
English (en)
Inventor
Dr Matthias Lohn
Dr Armin Hofmeister
Dr Joachim Brendel
Dr Oliver Plettenburg
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=38191090&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=UY30840(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of UY30840A1 publication Critical patent/UY30840A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/47—Quinolines; Isoquinolines
    • A61K31/472—Non-condensed isoquinolines, e.g. papaverine
    • A61K31/4725—Non-condensed isoquinolines, e.g. papaverine containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/08—Drugs for disorders of the urinary system of the prostate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/06—Antiabortive agents; Labour repressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/10—Drugs for genital or sexual disorders; Contraceptives for impotence
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
    • A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/02—Non-specific cardiovascular stimulants, e.g. drugs for syncope, antihypotensives
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
    • C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Neurosurgery (AREA)
  • Immunology (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Reproductive Health (AREA)
  • Urology & Nephrology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Communicable Diseases (AREA)
  • Pain & Pain Management (AREA)
  • Virology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Gynecology & Obstetrics (AREA)
  • Obesity (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Psychiatry (AREA)
  • Molecular Biology (AREA)

Abstract

La invencion se refiere a derivados de isoquinolina e isoquinolona 6-sustituidos de la formula (I), utiles para el tratamiento y/o prevencion de enfermedades asociadas con la Rho-quinasa de la fosfatasa de la cadena ligera de miosina, y a sus composiciones que contienen tales compuestos.
UY30840A 2006-12-27 2007-12-26 Derivados de isoquinolina e isoquinolinona sustituidos UY30840A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP06026898 2006-12-27

Publications (1)

Publication Number Publication Date
UY30840A1 true UY30840A1 (es) 2008-07-31

Family

ID=38191090

Family Applications (1)

Application Number Title Priority Date Filing Date
UY30840A UY30840A1 (es) 2006-12-27 2007-12-26 Derivados de isoquinolina e isoquinolinona sustituidos

Country Status (28)

Country Link
US (2) US8278294B2 (es)
EP (1) EP2102187B1 (es)
JP (1) JP5421783B2 (es)
KR (1) KR101517154B1 (es)
CN (1) CN101616909B (es)
AR (1) AR064533A1 (es)
AU (1) AU2007338406B2 (es)
BR (1) BRPI0720862A2 (es)
CA (1) CA2673916C (es)
CL (1) CL2007003822A1 (es)
CO (1) CO6321138A2 (es)
CR (1) CR10812A (es)
DO (1) DOP2009000163A (es)
EC (1) ECSP099466A (es)
HK (1) HK1140201A1 (es)
IL (1) IL199541A (es)
MA (1) MA31021B1 (es)
MX (1) MX2009005825A (es)
MY (1) MY150746A (es)
NI (1) NI200900107A (es)
NO (1) NO20092421L (es)
NZ (1) NZ577981A (es)
RU (1) RU2455302C2 (es)
TN (1) TN2009000270A1 (es)
TW (1) TWI435723B (es)
UY (1) UY30840A1 (es)
WO (1) WO2008077550A1 (es)
ZA (1) ZA200903550B (es)

Families Citing this family (42)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7470787B2 (en) 2005-07-11 2008-12-30 Aerie Pharmaceuticals, Inc. Isoquinoline compounds
EP2526948A1 (en) 2006-09-20 2012-11-28 Aerie Pharmaceuticals, Inc. RHO kinase inhibitors
US8455513B2 (en) 2007-01-10 2013-06-04 Aerie Pharmaceuticals, Inc. 6-aminoisoquinoline compounds
US8455514B2 (en) 2008-01-17 2013-06-04 Aerie Pharmaceuticals, Inc. 6-and 7-amino isoquinoline compounds and methods for making and using the same
CA3034994A1 (en) 2008-06-03 2009-12-10 Intermune, Inc. Substituted aryl-2 pyridone compounds and use thereof for treating inflammatory and fibrotic disorders
JP5715561B2 (ja) * 2008-06-24 2015-05-07 サノフイ 二及び多環式置換イソキノリン及びイソキノリノン誘導体
CN102131784B (zh) * 2008-06-24 2014-08-27 赛诺菲-安万特 作为rho激酶抑制剂的取代的异喹啉和异喹啉酮
MX2010013974A (es) * 2008-06-24 2011-01-14 Sanofi Aventis Isoquinolinas e isoquinolinonas 6-sustituidas.
US8450344B2 (en) 2008-07-25 2013-05-28 Aerie Pharmaceuticals, Inc. Beta- and gamma-amino-isoquinoline amide compounds and substituted benzamide compounds
CA2929545C (en) 2009-05-01 2019-04-09 Aerie Pharmaceuticals, Inc. Dual mechanism inhibitors for the treatment of disease
ES2568245T3 (es) 2011-07-08 2016-04-28 Sanofi Solvatos cristalinos de hidrocloruro de 6-(piperidin-4-iloxi)-2H-isoquinolin-1-ona
KR101959711B1 (ko) 2011-07-08 2019-03-19 사노피 치환된 페닐 화합물
HUE028550T2 (en) 2011-07-08 2016-12-28 Sanofi Sa Polymorphs of 6- (Piperidin-4-yloxy) -2H-isoquinolin-1-one hydrochloride
CN103160571A (zh) * 2011-12-09 2013-06-19 彩虹天健康科技研究(北京)有限责任公司 磷酸化肌球蛋白和驱动蛋白的激酶的发现
AR092742A1 (es) 2012-10-02 2015-04-29 Intermune Inc Piridinonas antifibroticas
EP3141235A1 (en) 2012-12-06 2017-03-15 IP Gesellschaft für Management mbH N-(6-((2r,3s)-3,4-dihydroxybutan-2-yloxy)-2-(4-fluorobenzylthio)pyrimidin-4-yl)-3-methylazetidine-l -sulfonamide
EP4335507A3 (en) 2013-03-15 2024-06-05 Aerie Pharmaceuticals, Inc. Combination therapy
ES2930305T3 (es) 2013-10-18 2022-12-09 Celgene Quanticel Res Inc Inhibidores del bromodominio
FR3017868A1 (fr) 2014-02-21 2015-08-28 Servier Lab Derives d'isoquinoleine, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
CN106459042B (zh) * 2014-04-02 2019-06-28 英特穆恩公司 抗纤维化吡啶酮类
MX2017008518A (es) 2014-12-24 2017-10-25 Gilead Sciences Inc Compuestos de isoquinolina para el tratamiento de virus de inmunodeficiencia humana (vih).
TWI770552B (zh) 2014-12-24 2022-07-11 美商基利科學股份有限公司 喹唑啉化合物
JP6385584B2 (ja) 2014-12-24 2018-09-05 ギリアード サイエンシーズ， インコーポレイテッド Ｈｉｖの処置のための縮合ピリミジン化合物
AR104259A1 (es) 2015-04-15 2017-07-05 Celgene Quanticel Res Inc Inhibidores de bromodominio
AU2015414743B2 (en) 2015-11-17 2019-07-18 Alcon Inc. Process for the preparation of kinase inhibitors and intermediates thereof
US9643927B1 (en) 2015-11-17 2017-05-09 Aerie Pharmaceuticals, Inc. Process for the preparation of kinase inhibitors and intermediates thereof
AU2017252276A1 (en) 2016-04-18 2018-11-15 Celgene Quanticel Research, Inc. Therapeutic compounds
US10150754B2 (en) 2016-04-19 2018-12-11 Celgene Quanticel Research, Inc. Histone demethylase inhibitors
MX2019002396A (es) 2016-08-31 2019-07-08 Aerie Pharmaceuticals Inc Composiciones oftalmicas.
WO2018049324A1 (en) 2016-09-12 2018-03-15 Numerate, Inc. Monocyclic compounds useful as gpr120 modulators
US10865201B2 (en) * 2016-09-12 2020-12-15 Valo Health, Inc. Bicyclic compounds useful as GPR120 modulators
MX2019011784A (es) 2017-03-31 2019-11-18 Aerie Pharmaceuticals Inc Compuestos de aril ciclopropil-amino-isoquinolinil amida.
HRP20230645T1 (hr) * 2018-02-02 2023-09-29 Genentech, Inc. Farmaceutski spoj, njegove soli, njegove formulacije i postupci izrade i upotrebe istih
CA3112391A1 (en) 2018-09-14 2020-03-19 Aerie Pharmaceuticals, Inc. Aryl cyclopropyl-amino-isoquinolinyl amide compounds
CN109180586B (zh) * 2018-10-10 2022-03-08 成都理工大学 作为Rho激酶抑制剂的六氢氮杂卓-4-基氧基苯甲酰胺类化合物
AU2019372046B2 (en) 2018-10-31 2022-05-26 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds as HPK1 inhibitors
EP3873608A1 (en) 2018-10-31 2021-09-08 Gilead Sciences, Inc. Substituted 6-azabenzimidazole compounds having hpk1 inhibitory activity
US11453681B2 (en) 2019-05-23 2022-09-27 Gilead Sciences, Inc. Substituted eneoxindoles and uses thereof
MX2023002165A (es) * 2020-08-27 2023-03-02 Woolsey Pharmaceuticals Inc Metodos para tratar el deterioro cognitivo relacionado con la edad.
US11738030B2 (en) 2021-10-30 2023-08-29 Aneuryst, Inc. Treatments for disturbed cerebral homeostasis
AU2022385051A1 (en) 2021-11-11 2024-06-20 Actualeyes Inc. Cryopreservation preparation for corneal endothelial cells and method for producing said cryopreservation preparation
WO2024030854A1 (en) * 2022-08-01 2024-02-08 Valo Health, Inc. Process for preparing 6-substituted-1-(2h)-isoquinolinones and intermediate compound

Family Cites Families (49)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2485537B2 (fr) 1977-04-13 1986-05-16 Anvar Dipyrido(4,3-b)(3,4-f)indoles, procede d'obtention, application therapeutique et compositions pharmaceutiques les contenant
EP0541559A1 (en) 1990-07-31 1993-05-19 E.I. Du Pont De Nemours And Company Catalytic equilibration of selected halocarbons
US5480883A (en) * 1991-05-10 1996-01-02 Rhone-Poulenc Rorer Pharmaceuticals Inc. Bis mono- and bicyclic aryl and heteroaryl compounds which inhibit EGF and/or PDGF receptor tyrosine kinase
GB9516709D0 (en) 1995-08-15 1995-10-18 Zeneca Ltd Medicament
ZA9610741B (en) 1995-12-22 1997-06-24 Warner Lambert Co 4-Substituted piperidine analogs and their use as subtype selective nmda receptor antagonists
PT956865E (pt) 1996-08-12 2007-07-30 Mitsubishi Pharma Corp Medicamentos compreendendo inibidores da rho cinase.
JPH1087629A (ja) 1996-09-18 1998-04-07 Fujisawa Pharmaceut Co Ltd 新規イソキノリン誘導体、およびその医薬用途
JP2001514259A (ja) 1997-08-29 2001-09-11 ゼネカ・リミテッド アミノメチルオキソオキサゾリジニルベンゼン誘導体
TW575567B (en) * 1998-10-23 2004-02-11 Akzo Nobel Nv Serine protease inhibitor
GB9912701D0 (en) 1999-06-01 1999-08-04 Smithkline Beecham Plc Novel compounds
US6541456B1 (en) 1999-12-01 2003-04-01 Isis Pharmaceuticals, Inc. Antimicrobial 2-deoxystreptamine compounds
CN1395575A (zh) * 2000-01-20 2003-02-05 卫材株式会社 新的哌啶化合物及其药物
US7217722B2 (en) * 2000-02-01 2007-05-15 Kirin Beer Kabushiki Kaisha Nitrogen-containing compounds having kinase inhibitory activity and drugs containing the same
US20040171533A1 (en) 2000-02-29 2004-09-02 Barbara Zehentner Methods and compositions for regulating adiopocytes
GB0004887D0 (en) 2000-03-01 2000-04-19 Astrazeneca Uk Ltd Chemical compounds
AR033517A1 (es) 2000-04-08 2003-12-26 Astrazeneca Ab Derivados de piperidina, proceso para su preparacion y uso de estos derivados en la fabricacion de medicamentos
GB0013060D0 (en) 2000-05-31 2000-07-19 Astrazeneca Ab Chemical compounds
WO2002034712A1 (fr) 2000-10-27 2002-05-02 Takeda Chemical Industries, Ltd. Procede de preparation de composes aromatiques substitues et produits intermediaires associes
WO2002055496A1 (en) 2001-01-15 2002-07-18 Glaxo Group Limited Aryl piperidine and piperazine derivatives as inducers of ldl-receptor expression
SE0101038D0 (sv) 2001-03-23 2001-03-23 Astrazeneca Ab Novel compounds
AU2002256418A1 (en) 2001-04-27 2002-11-11 Vertex Pharmaceuticals Incorporated Inhibitors of bace
JPWO2002100833A1 (ja) * 2001-06-12 2004-09-24 住友製薬株式会社 Ｒｈｏキナーゼ阻害剤
GB0117899D0 (en) 2001-07-23 2001-09-12 Astrazeneca Ab Chemical compounds
WO2003024450A1 (en) 2001-09-20 2003-03-27 Eisai Co., Ltd. Methods for treating prion diseases
SE0104340D0 (sv) 2001-12-20 2001-12-20 Astrazeneca Ab New compounds
WO2004009555A1 (ja) * 2002-07-22 2004-01-29 Asahi Kasei Pharma Corporation ５−置換イソキノリン誘導体
US7615564B2 (en) 2002-09-12 2009-11-10 Kirin Beer Kabushiki Kaisha Isoquinoline derivatives having kinasae inhibitory activity and drugs containing the same
CN100395237C (zh) * 2003-03-03 2008-06-18 弗·哈夫曼-拉罗切有限公司 用作5－ht6调节剂的2,5－取代的四氢异喹啉
US20040266755A1 (en) 2003-05-29 2004-12-30 Schering Aktiengesellschaft Prodrugs of 1-(1-hydroxy-5-isoquinolinesulfonyl) homopiperazine
EP1638939A2 (en) 2003-06-24 2006-03-29 Neurosearch A/S Aza-ring derivatives and their use as monoamine neurotransmitter re-uptake inhibitors
JP4718467B2 (ja) 2003-09-23 2011-07-06 メルク・シャープ・エンド・ドーム・コーポレイション イソキノリノンカリウムチャネル阻害剤
CA2539479C (en) 2003-09-23 2010-07-06 Merck & Co., Inc. Isoquinoline potassium channel inhibitors
US20050067037A1 (en) 2003-09-30 2005-03-31 Conocophillips Company Collapse resistant composite riser
US20070060595A1 (en) * 2003-10-10 2007-03-15 Toshio Yoshizawa Novel fused heterocyclic compound and use thereof
WO2005054202A1 (en) 2003-11-25 2005-06-16 Eli Lilly And Company 7-phenyl-isoquinoline-5-sulfonylamino derivatives as inhibitors of akt (proteinkinase b)
JP2005232175A (ja) * 2004-01-21 2005-09-02 Asahi Kasei Pharma Kk ５−置換イソキノリン医薬
WO2005074535A2 (en) 2004-01-30 2005-08-18 Eisai Co., Ltd. Cholinesterase inhibitors for spinal cord disorders
US20080312189A1 (en) 2004-03-05 2008-12-18 Eisai Co., Ltd. Cadasil Treatment with Cholinesterase Inhibitors
SE0400850D0 (sv) 2004-03-30 2004-03-31 Astrazeneca Ab Novel Compounds
US7517991B2 (en) * 2004-10-12 2009-04-14 Bristol-Myers Squibb Company N-sulfonylpiperidine cannabinoid receptor 1 antagonists
PT1899322E (pt) * 2005-06-28 2009-11-09 Sanofi Aventis Derivados de isoquinolina como inibidores de rho-cinase
BRPI0613861B8 (pt) * 2005-07-26 2021-05-25 Sanofi Aventis derivados de isoquinolona piperidinil-substituídos como inibidores de rho-cinase
RS52241B (en) 2005-07-26 2012-10-31 Sanofi CYCLOHEXYLAMINE ISOHINOLONE DERIVATIVES AS RHO-KINASE INHIBITORS
TW200745101A (en) 2005-09-30 2007-12-16 Organon Nv 9-Azabicyclo[3.3.1]nonane derivatives
TW200738682A (en) * 2005-12-08 2007-10-16 Organon Nv Isoquinoline derivatives
US7618985B2 (en) * 2005-12-08 2009-11-17 N.V. Organon Isoquinoline derivatives
US7893088B2 (en) * 2006-08-18 2011-02-22 N.V. Organon 6-substituted isoquinoline derivatives
ATE490243T1 (de) 2006-12-27 2010-12-15 Sanofi Aventis Cycloalkylaminsubstituierte isochinolin- und isochinolinonderivate
WO2008077555A2 (en) 2006-12-27 2008-07-03 Sanofi-Aventis Substituted isoquinolines and their use as rho-kinase inhibitors

Also Published As

Publication number Publication date
CA2673916A1 (en) 2008-07-03
CA2673916C (en) 2015-02-17
MX2009005825A (es) 2009-06-16
WO2008077550A1 (en) 2008-07-03
RU2009128645A (ru) 2011-02-10
AU2007338406A1 (en) 2008-07-03
US8278294B2 (en) 2012-10-02
IL199541A (en) 2014-08-31
CN101616909A (zh) 2009-12-30
AR064533A1 (es) 2009-04-08
BRPI0720862A2 (pt) 2014-02-25
CR10812A (es) 2009-08-12
AU2007338406B2 (en) 2012-08-09
NO20092421L (no) 2009-09-17
DOP2009000163A (es) 2009-08-31
US20100063025A1 (en) 2010-03-11
MY150746A (en) 2014-02-28
ZA200903550B (en) 2010-04-28
NZ577981A (en) 2011-12-22
RU2455302C2 (ru) 2012-07-10
CL2007003822A1 (es) 2009-10-16
KR20090094337A (ko) 2009-09-04
JP2010514715A (ja) 2010-05-06
ECSP099466A (es) 2009-07-31
JP5421783B2 (ja) 2014-02-19
EP2102187A1 (en) 2009-09-23
KR101517154B1 (ko) 2015-04-30
US8461144B2 (en) 2013-06-11
TWI435723B (zh) 2014-05-01
US20120316152A1 (en) 2012-12-13
EP2102187B1 (en) 2015-04-01
CN101616909B (zh) 2013-09-11
HK1140201A1 (en) 2010-10-08
CO6321138A2 (es) 2011-09-20
TN2009000270A1 (en) 2010-10-18
NI200900107A (es) 2010-01-15
TW200848043A (en) 2008-12-16
MA31021B1 (fr) 2009-12-01

Similar Documents

Publication Publication Date Title
UY30840A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos
UY30845A1 (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
ECSP099469A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
CR10814A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
DOP2006000177A (es) Derivados de ciclohexilaminisoquinolona
DOP2009000164A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
UY29697A1 (es) Derivados de isoquinolona sustituidos con piperidinilo
ATE554072T1 (de) Cycloalkylaminsubstituierte isochinolinderivate
CO6210725A2 (es) Derivados de isoquinolona e isoquinolinona sustituidos con cicloalquilamina
ECSP10010705A (es) Isoquinolinas e isoquinolinonas sustituidas en calidad de inhibidores de la rho-quinasa
CO6321249A2 (es) Isoquinolinas e isoquinolinonas 6-sustituidas
UY30841A1 (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
UY29698A1 (es) Derivados de ciclohexilaminisoquinolona
ECSP10010706A (es) Isoquinolinas e isoquinolinonas 6-sustituidas
DOP2009000154A (es) Nuevos derivados de isoquinolina e isoquinolinona sustituidos
DOP2009000153A (es) Derivados de isoquinolina e isoquinolinona sustituidos con cicloalquilamina
NI201000217A (es) Quinolinas e isoquinolinas 6 - sustituidas.